Bausch Health Companies Sees Unusually High Options Volume (NYSE:BHC)

Bausch Health Companies Inc. (NYSE:BHC) was the target of unusually large options trading activity on Wednesday. Investors bought 6,028 call options on the stock. This is an increase of approximately 54% compared to the average daily volume of 3,912 call options.

Hedge Funds Weigh In On Bausch Health Companies

Several hedge funds have recently bought and sold shares of BHC. Goldentree Asset Management LP boosted its position in shares of Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock worth $239,552,000 after acquiring an additional 6,958,717 shares in the last quarter. Vanguard Group Inc. lifted its stake in Bausch Health Companies by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company’s stock worth $94,460,000 after purchasing an additional 145,078 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Bausch Health Companies by 1.1% in the 4th quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company’s stock valued at $42,855,000 after purchasing an additional 56,446 shares in the last quarter. Maple Rock Capital Partners Inc. increased its stake in shares of Bausch Health Companies by 156.7% in the 4th quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company’s stock valued at $42,718,000 after purchasing an additional 3,235,100 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Bausch Health Companies by 46.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company’s stock worth $38,501,000 after buying an additional 1,510,445 shares during the last quarter. 78.65% of the stock is owned by institutional investors.

Bausch Health Companies Trading Down 2.8 %

Shares of BHC opened at $6.81 on Thursday. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $11.46. The firm’s 50 day moving average is $7.11 and its 200-day moving average is $7.71. The stock has a market capitalization of $2.50 billion, a PE ratio of -56.70, a P/E/G ratio of 0.37 and a beta of 0.59.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). The company had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. Equities research analysts predict that Bausch Health Companies will post 4.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Royal Bank of Canada lowered their price target on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a report on Thursday, January 30th. Jefferies Financial Group reiterated a “hold” rating and set a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Bausch Health Companies presently has an average rating of “Hold” and an average price target of $7.42.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.